On the public citation graph

Success of Drug Development for Cancer Diseases: Radicalness and Structural Holes

0 signed · 45 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.2018.7619openalex-extracted
Clinical Trial Evidence Supporting FDA Approval of Drugs Granted Breakthrough Therapy Designation
inferredcites →https://doi.org/10.1001/jama.300.9.1069openalex-extracted
Industry-Sponsored Clinical Research
inferredcites →https://doi.org/10.1002/smj.1956openalex-extracted
Technological development at the boundaries of the firm: a knowledge‐based examination in drug development
inferredcites →https://doi.org/10.1002/smj.2294openalex-extracted
The double‐edged sword of recombination in breakthrough innovation
inferredcites →https://doi.org/10.1002/smj.2615openalex-extracted
Firm heterogeneity in complex problem solving: A knowledge‐based look at invention
inferredcites →https://doi.org/10.1002/smj.634openalex-extracted
Old technology meets new technology: complementarities, similarities, and alliance formation
inferredcites →https://doi.org/10.1006/csla.2001.0169openalex-extracted
Normalization of non-standard words
inferredcites →https://doi.org/10.1016/j.jebo.2017.11.023openalex-extracted
The coevolution of endogenous knowledge networks and knowledge creation
inferredcites →https://doi.org/10.1016/j.jhealeco.2004.09.006openalex-extracted
Productivity in pharmaceutical–biotechnology R&D: the role of experience and alliances
inferredcites →https://doi.org/10.1016/j.respol.2010.03.001openalex-extracted
Knowledge sources, patent protection, and commercialization of pharmaceutical innovations
inferredcites →https://doi.org/10.1016/j.respol.2013.12.009openalex-extracted
When publications lead to products: The open science conundrum in new product development
inferredcites →https://doi.org/10.1016/j.respol.2020.104155openalex-extracted
Bridging the gap between invention and innovation: Increasing success rates in publicly and industry-funded clinical trials
inferredcites →https://doi.org/10.1016/j.techsoc.2020.101414openalex-extracted
How does external knowledge sourcing enhance product development? Evidence from drug commercialization
inferredcites →https://doi.org/10.1016/s0167-6296(02)00126-1openalex-extracted
The price of innovation: new estimates of drug development costs
inferredcites →https://doi.org/10.1016/s0191-3085(00)22009-1openalex-extracted
The Network Structure Of Social Capital
inferredcites →https://doi.org/10.1016/s0737-6782(01)00132-1openalex-extracted
A critical look at technological innovation typology and innovativeness terminology: a literature review
inferredcites →https://doi.org/10.1038/483531aopenalex-extracted
Raise standards for preclinical cancer research
inferredcites →https://doi.org/10.1038/clpt.2009.293openalex-extracted
Deconstructing the Drug Development Process: The New Face of Innovation
inferredcites →https://doi.org/10.1038/clpt.2010.286openalex-extracted
Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009
inferredcites →https://doi.org/10.1038/clpt.2013.117openalex-extracted
Clinical Approval Success Rates for Investigational Cancer Drugs
inferredcites →https://doi.org/10.1038/nbt.2786openalex-extracted
Clinical development success rates for investigational drugs
inferredcites →https://doi.org/10.1038/nrclinonc.2011.34openalex-extracted
High drug attrition rates—where are we going wrong?
inferredcites →https://doi.org/10.1038/nrd.2018.4openalex-extracted
2017 FDA drug approvals
inferredcites →https://doi.org/10.1038/nrd2290openalex-extracted
Molecular imaging in drug development
inferredcites →https://doi.org/10.1038/nrd3681openalex-extracted
Diagnosing the decline in pharmaceutical R&D efficiency
inferredcites →https://doi.org/10.1080/09537325.2016.1268682openalex-extracted
Sources of technological innovation: Radical and incremental innovation problem-driven to support competitive advantage of firms
inferredcites →https://doi.org/10.1080/14719037.2017.1302247openalex-extracted
Public–private collaborations in drug development: boosting innovation or alleviating risk?
inferredcites →https://doi.org/10.1108/14601061211220986openalex-extracted
Fostering radical innovations with open innovation
inferredcites →https://doi.org/10.1111/bcp.13240openalex-extracted
Affordable orphan drugs: a role for not‐for‐profit organizations
inferredcites →https://doi.org/10.1111/j.1467-9310.1994.tb00886.xopenalex-extracted
Managing industrial pharmaceutical R&D. A comparative study of management control and innovative effectiveness in European and Anglo‐American companies
inferredcites →https://doi.org/10.1111/jpim.12014openalex-extracted
Complements or Substitutes? Internal Technological Strength, Competitor Alliance Participation, and Innovation Development
inferredcites →https://doi.org/10.1111/jpim.12666openalex-extracted
How do different network positions affect crowd members' success in crowdsourcing challenges?
inferredcites →https://doi.org/10.1111/radm.12053openalex-extracted
Pharmaceutical new product development: why do clinical trials fail?
inferredcites →https://doi.org/10.1111/radm.12054openalex-extracted
Innovating the innovation process: an organisational experiment in global pharma pursuing radical innovation
inferredcites →https://doi.org/10.1111/radm.12308openalex-extracted
Who do you care about? Scientists’ personality traits and perceived impact on beneficiaries
inferredcites →https://doi.org/10.1146/annurev.soc.24.1.1openalex-extracted
Social Capital: Its Origins and Applications in Modern Sociology
inferredcites →https://doi.org/10.1200/jco.2006.09.0803openalex-extracted
Economics of New Oncology Drug Development
inferredcites →https://doi.org/10.2307/2393644openalex-extracted
Structural Holes: The Social Structure of Competition.
inferredcites →https://doi.org/10.2307/255553openalex-extracted
Organizational Structure, Work Process, and Proposal Making in Administrative Bureaucracies
inferredcites →https://doi.org/10.2307/2667032openalex-extracted
The Search-Transfer Problem: The Role of Weak Ties in Sharing Knowledge across Organization Subunits
inferredcites →https://doi.org/10.4324/9781315716510openalex-extracted
Medical Innovation
inferredcites →https://doi.org/10.48550/arxiv.1107.5743openalex-extracted
NEMO: Extraction and normalization of organization names from PubMed affiliation strings
inferredcites →https://doi.org/10.5210/disco.v5i0.3047openalex-extracted
NEMO: Extraction and normalization of organization names from PubMed affiliations
inferredcites →https://doi.org/10.5465/ambpp.2017.15393abstractopenalex-extracted
How do networks affect knowledge generation for drug development?
inferredcites →https://doi.org/10.5958/0974-360x.2020.00537.5openalex-extracted
Risk and Opportunities in Development of New Drug
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.